Abstract
We evaluated the efficacy of treatment with roxithromycin (RXM: new derivative of erythromycin) for OME patients with tympanostomy tube (TT) from the perspective of reducing refractory OME and preventing complications.Seventeen ears of 15 patients were treated for 6 months with a single daily dose (150mg) of RXM starting on the day of TT insertion. The other 23 ears of 20 patients were treated by TT insertion only.The rate of improvement, including “good” improvement, for ears with mucous fluid in the middle ear and poor mastoid pneumatization was significantly higher in ears treated with RXM (50%, 60%) than in ears treated with TT insertion alone (0%, 25%).These results indicate that low-dose RXM treatment may be useful for OME requiring TT insertion, and in reducing complications caused by TT insertion.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
